While significant therapeutic advances in squamous NSCLCs have been driven by the use of monoclonal antibodies targeting the PD1/PD-L1 pathway either alone or in combination with platinum-based doublet chemotherapy in the first-line treatment of advanced stages of disease, most patients still succumb to their metastatic disease.1 Here, CD274 is linked to metastatic neoplasm.